vol.7 January 2021

KOBE Biomedical Innovation Cluster newsletter vol.7
- January 2021 -

vol.7 January 2021　　

Hello,

　Time flies and it is already the end of January. In Japan, first 3 days of January is the period to celebrate New Year, and many of public offices, private companies and some retailers are closed. Year 2021 is year of the Ox in the Chinese Zodiac, and considered to be the year of patient, indicating a new beginning and development.

Once the new year comes, almost everything we do is first time of the year, of course, and there are unique ways to say and emphasize. "初 (Hatsu)" means "The first", and below are the typical wordings for some of "初" actions/scenes of the year.

初夢　(Hatsu-yume)　The first dream of the year

初笑い　(Hatsu-warai)　The first laugh of the year

初詣　(Hatsu-mode)　The first visit to temple and/or shrine of the year

初仕事　(Hatsu-shigoto) The first working day of the year

初日の出　(Hatsu-hinode) The first sunrise of the year

【初日の出】

This is our "初" Hatsu-KBIC Newsletter this year If you missed any of our past news topics, please visit KBIC Website "News and events" page (https://www.fbrikobe.org/kbic/english/news/).

May the year of 2021 bring you a lot of love, happiness and smiles!

FBRI Editorial Team

News

Sysmex Corporation Obtains Marketing Approval for the HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients

(Published: December 23, 2020)

Sysmex Corporation obtained marketing approval on December 22, 2020 for the HISCL IFN-λ3 reagent, an interferon-λ3 kit.

Oncolys BioPharma Inc. and ASAHI INTEC CO.,LTD. Announces Conclusion of Capital and Business Alliance

(Published: December 10, 2020)

Oncolys BioPharma is pleased to announce that the board of the company resolved to enter into a capital and business alliance agreement with Asahi Intecc Co., Ltd., one of the world's leading medical device producer specialized in guide wires and catheter products, to continue to develop efficient and better medical devices for easier and more precise administration of oncolytic viruses.

Dr. Masayo Takahashi, President of Vision Care, Inc. as part of Kobe Eye Center; Director of RIKEN Center for Biosystems Dynamics Research has received The Greenberg Prize - End Blindness 2020 - Visionary Award

(Published: December 28, 2020)

End Blindness 2020 - an unprecedented joint effort by leading scientists and figures from the worlds of business, politics, culture, art, music and entertainment to rid the world of blindness - is about to mark a major milestone.

Kobe University and Sysmex Corporation Conducted Clinical Evaluation of the ELISPOT Method: A New Test for COVID-19 using blood - Report on T cell Immunity to SARS-CoV-2 in the Japanese Population -

(Published: December 24, 2020)

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

JCR Pharmaceuticals Co., Ltd. Signs Provisional Production Master Service Agreement with AstraZeneca Regarding Domestic Production of COVID-19 Vaccine Bulk Product

(Published: December 30, 2020)

JCR Pharmaceuticals Co., Ltd. announced that it has signed a provisional production master service agreement with AstraZeneca K.K. regarding the production of bulk product in Japan for the adenovirus vector-based COVID-19 vaccine, known as AZD1222 . The vaccine is currently being developed by AstraZeneca.

HACARUS INC. named Best Japanese Startup/SME for the French/European Market

(Published: December 7, 2020)

HACARUS INC. was named Best Japanese Startup/SME for the French/European Market by CACIB, Le Village by CA, Norinchukin Bank and AgVenture Lab on December 3, 2020.

T-ICU Co., Ltd. raises a total of 153 million yen from Beyond Next Ventures Inc. and others

(Published: January 5, 2021)

T-ICU Co., Ltd., a member of Kobe Biomedical Innovation Cluster, which provides remote intensive care solutions by specialists, has announced that it has raised a total of 153 million yen through a third-party allocation of new shares on December 28, 2020.